

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application Number		10551847
	Filing Date		2006-06-23
	First Named Inventor	HAIXIANG, LIN	
	Art Unit	1648	
	Examiner Name	LE, EMILY M	
	Attorney Docket Number	NBMP-001(SP)	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3692899		1972-09-19	Levy, H.	
	2	3906092		1975-09-16	Hilleman, M., et al.	
	3	4082735		1978-04-04	Jones, G., et al.	
	4	4082736		1978-04-04	Jones, G., et al.	
	5	4094971		1978-06-13	Chedid, L., et al.	
	6	4101536		1978-07-18	Yamamura, Y., et al.	
	7	4124702		1978-11-07	Lampson, G., et al.	
	8	4153684		1979-05-08	Audibert, F., et al.	

Application Number	10551847	10551847 - GAU: 1648
Filing Date	2006-06-23	
First Named Inventor	HAIXIANG, LIN	
Art Unit	1648	
Examiner Name	LE, EMILY M	
Attorney Docket Number	NBMP-001(SP)	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

9	4185089		1980-01-22	Derrien, M., et al.	
10	4186194		1980-01-29	Adam, A., et al.	
11	4235771		1980-11-25	Adam, A., et al.	
12	4314998		1982-02-09	Yamamura, Y., et al.	
13	4323559		1982-04-06	Audibert, F., et al.	
14	4327085		1982-04-27	Audibert, F., et al.	
15	4369178		1983-01-18	Yamamura, Y., et al.	
16	6008200		1999-28-12	Krieg, A., et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

**U.S. PATENT APPLICATION PUBLICATIONS**

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20070166800	A1	2007-07-19	HAIXIANG, L.	

Application Number	10551847	10551847 - GAU: 1648
Filing Date	2006-06-23	
First Named Inventor	HAIXIANG, LIN	
Art Unit	1648	
Examiner Name	LE, EMILY M	
Attorney Docket Number	NBMP-001(SP)	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

	2	20070166239	A1	2007-07-19	HAIXIANG, L.	
--	---	-------------	----	------------	--------------	--

If you wish to add additional U.S. Published Application citation information please click the Add button [Add](#)

**FOREIGN PATENT DOCUMENTS**

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	JP01093540	JP	A2	1989-04-12	Mount Sinai Hospital Corp		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

**NON-PATENT LITERATURE DOCUMENTS**

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	ELLOUZ, F., et al. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochemical and Biophysical Research Communications. 1974, vol. 59, no. 4, pp. 1317-1325.	<input type="checkbox"/>
	2	GUPTA, R. K., et al. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine. 1995, vol. 13, no. 14, pp. 1263-1278.	<input type="checkbox"/>
	3	GUPTA, R. K., et al. Adjuvants - a balance between toxicity and adjuvant activity. Vaccine. 1993, vol. 11, pp. 293-306.	<input type="checkbox"/>
	4	KANZLER, H., et al. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nature Medicine. 2007, vol. 13, no. 5, pp 552-559. E-pub 3 May 2007.	<input type="checkbox"/>
	5	KENNEY, R. T., et al. Meeting report, 2nd meeting on novel adjuvants currently in/close to human clinical testing, World Health Organization - Organization Mondiale de la Sante, Fondation Merieux, Annecy, France, 5-7 June 2000. Vaccine. 2002, vol. 20, pp. 2155-2163.	<input type="checkbox"/>

Receipt date: 12/18/2007

Application Number 10551847

10551847 - GAU: 1648

Filing Date 2006-06-23

First Named Inventor HAI XIANG, LIN

Art Unit 1648

Examiner Name LE, EMILY M

Attorney Docket Number NBMP-001(SP)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

6	MORAHAN, P. S., et al. Antiviral activity and side effects of polyribonucleoside-cytidylic acid complexes as affected by molecular size. Proceedings of the National Academy of Sciences USA. 1972, vol. 69, no. 4, pp. 842-846.	<input type="checkbox"/>
7	NORLUND, J. J., et al. Inhibition of biologic activity of Poly I: Poly C by human plasma (34492). Proc Soc Exp Biol Med. 1970, vol. 133, pp. 439-444.	<input type="checkbox"/>
8	PHILLIPS, B. M., et al. Systemic toxicity of polyinosinic acid: polycytidylic acid in rodents and dogs. Toxicology and Applied Pharmacology. 1971, vol. 18, pp. 220-230.	<input type="checkbox"/>
9	SELA, M. Antigenicity: some molecular aspects. Science. 1969, vol. 166, pgs. 1365-1374.	<input type="checkbox"/>
10	STERN, R. A nuclease from animal serum which hydrolyzes double-stranded RNA. Biochemical and Biophysical Research Communications. 1970, vol. 41, no. 3, pp. 608-614.	<input type="checkbox"/>
11	WRIGHT, C. L., et al. The adjuvant effects mycoviral dsRNA and polyinosinic:polycytidylic acid on the murine immune response. Biochemical and Biophysical Research Communications. 1985, vol. 131, no. 2, pp. 949-955.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button 

## EXAMINER SIGNATURE

Examiner Signature	/Emily Le/	Date Considered	01/28/2009
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.